Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622720 | 1.00 | HDAC6 (0.54) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL622318 | 1.00 | HDAC6 (0.54) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL30262738 | 0.85 | HDAC3 (0.45) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19871362 | 0.80 | CYP2D6 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL9953255 | 0.80 | CYP2D6 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16842413 | 0.78 | HDAC3 (0.33) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL24445633 | 0.77 | HDAC3 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL14524872 | 0.77 | HDAC3 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28507298 | 0.77 | HDAC3 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16447084 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0351214-A1 | Anti-inflammatory aryl derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-17 | — | — | EP | claimed |
| US-12171772-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2023-09-07 | — | — | US | disclosed |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2023-09-07 | — | — | US | disclosed |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220125813-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2022-04-28 | — | — | US | disclosed |
| EP-3666778-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2020-07-16 | — | — | US | disclosed |
| US-20150119363-A1 | METHODS OF TREATING BACTERIAL INFECTIONS | Rempex Pharmaceuticals, Inc.. (US) | 2015-04-30 | — | — | US | disclosed |
| EP-2814483-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | Rempex Pharmaceuticals, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-8680136-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680136-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20130345172-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| WO-2013122888-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | REMPEX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2603514-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120040932-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040932-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2012021455-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-20220125813-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-20120040932-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BCL9 | HDAC6 849/4885HDAC3 2302/4885HDAC1 2058/4885 |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-12171772-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-20130345172-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BCL9 | HDAC6 849/4885HDAC3 2302/4885HDAC1 2058/4885 |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-20150119363-A1 | METHODS OF TREATING BACTERIAL INFECTIONS | MMP8, ELANE, LCT | HDAC6 754/4885HDAC3 1531/4885HDAC1 1677/4885 |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.